Back to portfolio

NuProbe Global

Developer of ultra-sensitive and highly multiplexed platform with reagents for non-invasive nucleic acid profiling and diagnostics

Developer of a technology designed to make non-invasive early detection of rare genetic variants in patients. The company's technology takes a multi-platform approach to apply precision medicine to cancer diagnostics, NIPT and infectious disease.

Area
Life Sciences
Location
Shanghai
Investment year
2020
Organization type
For-profit
Status
Active